The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice

Int J Neuropsychopharmacol. 2020 Dec 10;23(10):700-711. doi: 10.1093/ijnp/pyaa048.

Abstract

Background: Depression is highly related to Alzheimer's disease (AD), yet no effective treatment is available. Phosphodiesterase-4 (PDE4) has been considered a promising target for treatment of AD and depression. Roflumilast, the first PDE4 inhibitor approved for clinical use, improves cognition at doses that do not cause side effects such as emesis.

Methods: Here we examined the effects of roflumilast on behavioral dysfunction and the related mechanisms in APPswe/PS1dE9 transgenic mice, a widely used model of AD. Mice at 10 months of age were examined for memory in the novel object recognition and Morris water-maze tests and depression-like behavior in the tail-suspension test and forced swimming test before killing for neurochemical assays.

Results: In the novel object recognition and Morris water-maze, APPswe/PS1dE9 mice showed significant cognitive declines, which were reversed by roflumilast at 5 and 10 mg/kg orally once per day. In the tail-suspension test and forced swimming test, the AD mice showed prolonged immobility time, which was also reversed by roflumilast. In addition, the staining of hematoxylin-eosin and Nissl showed that roflumilast relieved the neuronal cell injuries, while terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling analysis indicated that roflumilast ameliorated cell apoptosis in AD mice. Further, roflumilast reversed the decreased ratio of B-cell lymphoma-2/Bcl-2-associated X protein and the increased expression of PDE4B and PDE4D in the cerebral cortex and hippocampus of AD mice. Finally, roflumilast reversed the decreased levels of cyclic AMP (cAMP) and expression of phosphorylated cAMP response element-binding protein and brain derived neurotrophic factor in AD mice.

Conclusions: Together, these results suggest that roflumilast not only improves learning and memory but also attenuates depression-like behavior in AD mice, likely via PDE4B/PDE4D-mediated cAMP/cAMP response element-binding protein/brain derived neurotrophic factor signaling. Roflumilast can be a therapeutic agent for AD, in particular the comorbidity of memory loss and depression.

Keywords: Alzheimer’s disease; Roflumilast; depression; phosphodiesterase-4 (PDE4); β-amyloid (Aβ).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Aminopyridines / administration & dosage
  • Aminopyridines / pharmacology*
  • Amyloid beta-Protein Precursor
  • Animals
  • Behavior, Animal / drug effects
  • Benzamides / administration & dosage
  • Benzamides / pharmacology*
  • Cerebral Cortex / drug effects*
  • Cyclopropanes / administration & dosage
  • Cyclopropanes / pharmacology
  • Depression / drug therapy*
  • Disease Models, Animal
  • Hippocampus / drug effects
  • Maze Learning / drug effects
  • Memory Disorders / drug therapy*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Phosphodiesterase 4 Inhibitors / administration & dosage
  • Phosphodiesterase 4 Inhibitors / pharmacology*
  • Presenilin-1
  • Recognition, Psychology / drug effects

Substances

  • APP protein, human
  • APP protein, mouse
  • Aminopyridines
  • Amyloid beta-Protein Precursor
  • Benzamides
  • Cyclopropanes
  • PSEN1 protein, human
  • Phosphodiesterase 4 Inhibitors
  • Presenilin-1
  • Roflumilast